NCT Number: NCT05939414
Phase: PHASE3
Trial Summary: The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Novartis Pharmaceuticals
Acronym: PSMA-DC
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives